CXCL9 and neoplasm: Although there is some question as to whether our findings in blood are representative of the tumor microenvironment, a study of mRCC including patients receiving nivolumab suggested a correlation between chemokines such as CXCL9 and CXCL10 in simultaneously collected serum and on-treatment biopsy samples32.